Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820332 | 0.72 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2HPGDCHRNA7ALPL | |
| SCHEMBL13058695 | 0.69 | CHRNA7 (0.39) | ALDH1A1SMN1; SMN2HPGDCHRNA7ALPL | |
| SCHEMBL10284897 | 0.68 | CHRNA7 (0.40) | ALDH1A1SMN1; SMN2HPGDCHRNA7EGFR | |
| SCHEMBL14299651 | 0.67 | CHRNA7 (0.49) | ALDH1A1SMN1; SMN2HPGDCHRNA7EGFR | |
| SCHEMBL26971207 | 0.65 | CDK2 (0.37) | ALDH1A1SMN1; SMN2HPGDCHRNA7ALPL | |
| SCHEMBL20889617 | 0.65 | CHRNA7 (0.36) | ALDH1A1SMN1; SMN2HPGDCHRNA7EGFR | |
| SCHEMBL3439349 | 0.62 | CCR1 (0.39) | ALDH1A1HPGDHTT | |
| SCHEMBL23564267 | 0.60 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2HPGDCHRNA7ALPL | |
| SCHEMBL13809968 | 0.60 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2HPGDCHRNA7ALPL | |
| SCHEMBL13358899 | 0.60 | ROCK1 (0.34) | EGFRTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | ALDH1A1 3871/4885SMN1; SMN2 2169/4885HPGD 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.